InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Hollander David, Directeur de la R&D. Director active across 1 companies, notably Aerie Pharmaceuticals INC. Aggregated, 4 filings have been published. The latest transaction was filed on 4 February 2022 — Retenue fiscale. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations4 total
€5,715927 shares@ €6.164920.1% of flow
Common Stock
SEC:0001209191-22-007902·
€5,715927 shares@ €6.164910.1% of flow
Common Stock
SEC:0001209191-22-007902:0·
€22,7012,162 shares@ €10.499879.9% of flow
Common Stock
SEC:0001209191-21-064473·
€22,7012,162 shares@ €10.499839.9% of flow
Common Stock
SEC:0001209191-21-064473:0·
4 of 4 declarations
About Hollander David
David Hollander is the Chief R&D Officer at Aerie Pharmaceuticals Inc. He oversees the research and development activities of the company, which specializes in the pharmaceutical sector. His role is essential for innovation and the development of new products at Aerie.
